Novel investigational therapeutics for generalized anxiety disorder (GAD)

References

• Anxiety and Depression Association of America. Understand the facts: generalized anxiety disorder. [cited 2019 Jul 17]. Available from: https://adaa.org/understanding-anxiety/generalized-anxiety-disorder-gad
   Google Scholar
• Baldwin D, Stein MB, Hermann R. Generalized anxiety disorder in adults: epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis. UpToDate; 2018. Available from: https://www.uptodate.com/contents/generalized-anxiety-disorder-in-adults-epidemiology-pathogenesis-clinical-manifestations-course-assessment-and-diagnosis
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Association; 2013.
   Google Scholar
• Crocq M-A. The history of generalized anxiety disorder as a diagnostic category. Dialogues Clin Neurosci. 2017;19:107–116.
   PubMed Web of Science ®Google Scholar
• Breslau N, Davis GC. DSM-III generalized anxiety disorder: an empirical investigation of more stringent criteria. Psychiatry Res. 1985;15:231–238.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 changes on the national survey on drug use and health; 2016 June.
   Google Scholar
• Shin LM, Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacology. 2010;35:169–191.
   PubMed Web of Science ®Google Scholar
• Etkin A, Wager TD. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am J Psychiatry. 2007;164:1476–1488.
   PubMed Web of Science ®Google Scholar
• Fonzo GA, Etkin A. Affective neuroimaging in generalized anxiety disorder: an integrated review. Dialogues Clin Neurosci. 2017;19:169–179.
   PubMed Web of Science ®Google Scholar
• Feinstein JS, Adolphs R, Damasio A, et al. The human amygdala and the induction and experience of fear. Curr Biol. 2011;21:34–38.
   PubMed Web of Science ®Google Scholar
• Craig AD. Interoception: the sense of the physiological condition of the body. Curr Opin Neurobiol. 2003;13:500–505.
   PubMed Web of Science ®Google Scholar
• Fonzo GA, Ramsawh HJ, Flagan TM, et al. Common and disorder-specific neural responses to emotional faces in generalised anxiety, social anxiety and panic disorders. Br J Psychiatry. 2015;206:206–215.
   PubMed Web of Science ®Google Scholar
• McClure EB, Monk CS, Nelson EE, et al. Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry. 2007;64:97–106.
   PubMed Web of Science ®Google Scholar
• Blair K, Shaywitz J, Smith BW, et al. Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry. 2008;165:1193–1202.
   PubMed Web of Science ®Google Scholar
• Whalen PJ, Johnstone T, Somerville LH, et al. A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder. Biol Psychiatry. 2008;63:858–863.
   PubMed Web of Science ®Google Scholar
• Karim H, Tudorascu DL, Aizenstein H, et al. Emotion reactivity and cerebrovascular burden in late-life GAD: a neuroimaging study. Am J Geriatr Psychiatry. 2016;24:1040–1050.
   PubMed Web of Science ®Google Scholar
• Paulesu E, Sambugaro E, Torti T, et al. Neural correlates of worry in generalized anxiety disorder and in normal controls: a functional MRI study. Psychol Med. 2010;40:117–124.
   PubMed Web of Science ®Google Scholar
• Andreescu C, Sheu LK, Tudorascu D, et al. Emotion reactivity and regulation in late-life generalized anxiety disorder: functional connectivity at baseline and post-treatment. Am J Geriatr Psychiatry. 2015;23:200–214.
   PubMed Web of Science ®Google Scholar
• Andreescu C, Sheu LK, Tudorascu D, et al. The ages of anxiety–differences across the lifespan in the default mode network functional connectivity in generalized anxiety disorder. Int J Geriatr Psychiatry. 2014;29:704–712.
   PubMed Web of Science ®Google Scholar
• Mohlman J, Eldreth DA, Price RB, et al. Prefrontal-limbic connectivity during worry in older adults with generalized anxiety disorder. Aging Ment Health. 2017;21:426–438.
   PubMed Web of Science ®Google Scholar
• Hettema JM, Prescott CA, Kendler KS. A population-based twin study of generalized anxiety disorder in men and women. J Nerv Ment Dis. 2001;189:413–420.
   PubMed Web of Science ®Google Scholar
• Mather L, Blom V, Bergstrom G, et al. An underlying common factor, influenced by genetics and unique environment, explains the covariation between major depressive disorder, generalized anxiety disorder, and burnout: a Swedish twin study. Twin Res Hum Genet. 2016;19:619–627.
   PubMed Web of Science ®Google Scholar
• Tadic A, Rujescu D, Szegedi A, et al. Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. Am J Med Genet B Neuropsychiatr Genet. 2003;117B:1–6.
   PubMed Web of Science ®Google Scholar
• You J-S, Hu S-Y, Chen B, et al. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet. 2005;15:7–11.
   PubMed Web of Science ®Google Scholar
• Montag C, Basten U, Stelzel C, et al. The BDNF Val66Met polymorphism and anxiety: support for animal knock-in studies from a genetic association study in humans. Psychiatry Res. 2010;179:86–90.
   PubMed Web of Science ®Google Scholar
• Klauke B, Deckert J, Zwanzger P, et al. Neuropeptide S receptor gene (NPSR) and life events: G x E effects on anxiety sensitivity and its subdimensions. World J Biol Psychiatry. 2014;15:17–25.
   PubMed Web of Science ®Google Scholar
• Baumann C, Klauke B, Weber H, et al. The interaction of early life experiences with COMT val158met affects anxiety sensitivity. Genes Brain Behav. 2013;12:821–829.
   PubMed Web of Science ®Google Scholar
• Gottschalk MG, Domschke K. Genetics of generalized anxiety disorder and related traits. Dialogues Clin Neurosci. 2017;19:159–168.
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP. The GABA-benzodiazepine receptor complex: structure, function, and role in anxiety. J Clin Psychiatry. 2005;66(Suppl 2):14–20.
   PubMed Web of Science ®Google Scholar
• Griebel G, Sanger DJ, Perrault G. Further evidence for differences between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands in murine models of ‘state’ and ‘trait’ anxiety. Neuropharmacology. 1996;35:1081–1091.
   PubMed Web of Science ®Google Scholar
• Atack JR, Hutson PH, Collinson N, et al. Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. Br J Pharmacol. 2005;144:357–366.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Kuikka J, Rasanen P, et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry. 1997;2:463–471.
   PubMed Web of Science ®Google Scholar
• Malizia AL, Cunningham VJ, Bell CJ, et al. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715–720.
   PubMed Web of Science ®Google Scholar
• Li Y-F, Jackson KL, Stern JE, et al. Interaction between glutamate and GABA systems in the integration of sympathetic outflow by the paraventricular nucleus of the hypothalamus. Am J Physiol Heart Circ Physiol. 2006;291:H2847–56.
   PubMed Web of Science ®Google Scholar
• Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology. 2008;33:1603–1610.
   PubMed Web of Science ®Google Scholar
• Sugiyama A, Saitoh A, Iwai T, et al. Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines. Neuropharmacology. 2012;62:2489–2498.
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Amiel JM, Coplan JD, et al. Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry. 2005;162:2379–2381.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Li Y, Soeller I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol. 2009;29:378–382.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry. 2012;73:1002–1008.
   PubMed Web of Science ®Google Scholar
• Sowa-Kucma M, Panczyszyn-Trzewik P, Misztak P, et al. Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep. 2017;69:595–601.
   PubMed Web of Science ®Google Scholar
• Lundbeck H A clinical trial results: a double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD). [cited 2019 Sept 20]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-001673-15/results.
   Google Scholar
• AstraZeneca. AZD7325: mechanism of action: gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAAα2,3) positive modulator. [cited 2019 Jul 26]. Available from: https://openinnovation.astrazeneca.com/azd7325.html.
   Google Scholar
• Artelsmair M, Gu C, Lewis RJ, et al. Synthesis of C-14 labeled GABAA alpha2/alpha3 selective partial agonists and the investigation of late-occurring and long-circulating metabolites of GABAA receptor modulator AZD7325. J Labelled Comp Radiopharm. 2018;61:415–426.
   PubMed Web of Science ®Google Scholar
• Gu C, Artelsmair M, Elmore CS, et al. Late-occurring and long-circulating metabolites of GABAAalpha2,3 receptor modulator AZD7325 involving metabolic cyclization and aromatization: relevance to MIST analysis and application for patient compliance. Drug Metab Dispos. 2018;46:303–315.
   PubMed Web of Science ®Google Scholar
• Savage KM, Stough CK, Byrne GJ, et al. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Trials. 2015;16:493.
   PubMed Web of Science ®Google Scholar
• Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45:27–35.
   PubMed Web of Science ®Google Scholar
• Nickolls SA, Gurrell R, van Amerongen G, et al. Pharmacology in translation: the preclinical and early clinical profile of the novel alpha2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865. Br J Pharmacol. 2018;175:708–725.
   PubMed Web of Science ®Google Scholar
• Birla H, Keswani C, Rai SN, et al. Neuroprotective effects of withania somnifera in BPA induced-cognitive dysfunction and oxidative stress in mice. Behav Brain Funct. 2019;15:9.
   PubMed Web of Science ®Google Scholar
• Yenisetti SC, Manjunath MJ, Muralidhara C. Neuropharmacological properties of withania somnifera - Indian ginseng: an overview on experimental evidence with emphasis on clinical trials and patents. Recent Pat CNS Drug Discov. 2016;10:204–215.
   PubMedGoogle Scholar
• Pratte MA, Nanavati KB, Young V, et al. An alternative treatment for anxiety: a systematic review of human trial results reported for the ayurvedic herb ashwagandha (withania somnifera). J Altern Complement Med. 2014;20:901–908.
   PubMed Web of Science ®Google Scholar
• Srivastava JK, Shankar E, Chamomile GS. A herbal medicine of the past with bright future. Mol Med Rep. 2010;3:895–901.
   PubMed Web of Science ®Google Scholar
• Mao JJ, Xie SX, Keefe JR, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial. Phytomedicine. 2016;23:1735–1742.
   PubMed Web of Science ®Google Scholar
• Scott S, Aricescu AR. A structural perspective on GABAA receptor pharmacology. Curr Opin Struct Biol. 2019;54:189–197.
   PubMed Web of Science ®Google Scholar
• de Boer JN, Vingerhoets C, Hirdes M, et al. Efficacy and tolerability of riluzole in psychiatric disorders: a systematic review and preliminary meta-analysis. Psychiatry Res. 2019;278:294–302.
   PubMed Web of Science ®Google Scholar
• Herrera-Arellano A, Jimenez-Ferrer JE, Zamilpa A, et al. Therapeutic effectiveness of Galphimia glauca vs lorazepam in generalized anxiety disorder. A controlled 15-week clinical trial. Planta Med. 2012;78:1529–1535.
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JR. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry. 1998;44:1286–1294.
   PubMed Web of Science ®Google Scholar
• Huang X, Yang J, Yang S, et al. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms. Oncotarget. 2017;8:102705–102720.
   PubMedGoogle Scholar
• Buoli M, Grassi S, Serati M, et al. Agomelatine for the treatment of generalized anxiety disorder. Expert Opin Pharmacother. 2017;18:1373–1379.
   PubMed Web of Science ®Google Scholar
• Pae C-U, Wang S-M, Han C, et al. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res. 2015;64:88–98.
   PubMed Web of Science ®Google Scholar
• Risbrough VB, Stein MB. Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav. 2006;50:550–561.
   PubMed Web of Science ®Google Scholar
• McCall JG, Al-Hasani R, Siuda ER, et al. CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron. 2015;87:605–620.
   PubMed Web of Science ®Google Scholar
• Hodgetts KJ, Ge P, Yoon T, et al. Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyra zin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. J Med Chem. 2011;54:4187–4206.
   PubMed Web of Science ®Google Scholar
• Zhou L, Dockens RC, Liu-Kreyche P, et al. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist. Drug Metab Dispos. 2012;40:1093–1103.
   PubMed Web of Science ®Google Scholar
• Zorrilla EP, Heilig M, de Wit H, et al. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013;128:175–186.
   PubMed Web of Science ®Google Scholar
• Coric V, Feldman HH, Oren DA, et al. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety. 2010;27:417–425.
   PubMed Web of Science ®Google Scholar
• Brown AJ. Novel cannabinoid receptors. Br J Pharmacol. 2007;152:567–575.
   PubMed Web of Science ®Google Scholar
• Drugbank. Cannabidiol. [cited 26 July 2019]. Available from: www.drugbank.ca/drugs/DB09061.
   Google Scholar
• Taylor Levine M, Gao J, Satyanarayanan SK, et al. S-adenosyl-l-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: clinical and mechanistic considerations. Brain Behav Immun. 2019 July. DOI:10.1016/j.bbi.2019.07.013.
   PubMed Web of Science ®Google Scholar
• Chaperon F, Thiebot MH. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol. 1999;13:243–281.
   PubMedGoogle Scholar
• Haller J, Freund TF, Pelczer KG, et al. The anxiolytic potential and psychotropic side effects of an echinacea preparation in laboratory animals and healthy volunteers. Phytother Res. 2013;27:54–61.
   PubMed Web of Science ®Google Scholar
• Woelkart K, Xu W, Pei Y, et al. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med. 2005;71:701–705.
   PubMed Web of Science ®Google Scholar
• Park J-A, Lee C-H. Effect of rufinamide on the kainic acid-induced excitotoxic neuronal death in the mouse hippocampus. Arch Pharm Res. 2018;41:776–783.
   PubMed Web of Science ®Google Scholar
• Chen BH, Ahn JH, Park JH, et al. Rufinamide, an antiepileptic drug, improves cognition and increases neurogenesis in the aged gerbil hippocampal dentate gyrus via increasing expressions of IGF-1, IGF-1R and p-CREB. Chem Biol Interact. 2018;286:71–77.
   PubMed Web of Science ®Google Scholar
• Young A, Patrick F, Wise T. Modulation of anxiety-relevant neural circuits in generalized anxiety disorder: a novel cholinergic system pharmacotherapy approach. Soc. Biol. Psychiatry Annu. Meet., New York; 2017.
   Google Scholar
• Agarwal SD, Landon BE. Patterns in outpatient benzodiazepine prescribing in the United States. JAMA Network Open. 2019;2:e187399.
   PubMed Web of Science ®Google Scholar
• McClure FL, Niles JK, Kaufman HW, et al. Concurrent use of opioids and benzodiazepines: evaluation of prescription drug monitoring by a United States laboratory. J Addict Med. 2017;11:420–426.
   PubMed Web of Science ®Google Scholar
• Bandelow B, Sher L, Bunevicius R, et al. WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Int J Psychiatry Clin Pract. 2012Jun;16(2):77–84. doi: 10.3109/13651501.2012.667114. PMID: 22540422.
   PubMed Web of Science ®Google Scholar
• Sohal VS, Rubenstein JLR. Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol Psychiatry. 2019;24:1248–1257.
   PubMed Web of Science ®Google Scholar
• Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med. 2019;381:903–911.
   PubMed Web of Science ®Google Scholar
• Mayo LM, Asratian A, Lindé J, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2019. in press.
   PubMed Web of Science ®Google Scholar
• Doros G, Pencina M, Rybin D, et al. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. Stat Med. 2013;32:2767–2789.
   PubMed Web of Science ®Google Scholar
• Bartova L, Dold M, Kautzky A, et al. Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. World J Biol Psychiatry. 2019;20(6):427–448.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Woldeyohannes HO, Soczynska JK, et al. The prevalence and clinical characteristics associated with diagnostic and statistical manual version-5 defined anxious distress specifier in adults with major depressive disorder: results from the international mood disorders collaborative project. Ther Adv Chronic Dis. 2016;7(3):153–159.
   PubMed Web of Science ®Google Scholar
• Thase ME, Weiller E, Zhang P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies. Neuropsychiatr Dis Treat. 2018;15:37–45.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Kiselycznyk C, Banasr M, et al. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J Affect Disord. 2018;241:514–518.
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Price RB, Mao X, et al. Serum and Hippocampal N-acetylaspartate concentration and response to riluzole in generalized anxiety disorder. Biol Psychiatry. 2008;63:891–898.
   PubMed Web of Science ®Google Scholar
• Abdallah CG, Coplan JD, Jackowski A, et al. A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD. Eur Neuropsychopharmacol. 2013;23:276–284.
   PubMed Web of Science ®Google Scholar